Anukul Ghimire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anukul Ghimire has a total of 437 co-authors. Here are the top co-authors by number of shared publications:
Feng Ye
Medicine, University of Alberta, Edmonton, Alberta, Canada
17 shared publicationsKailash Jindal
Medicine, University of Alberta, Edmonton, Alberta, Canada
13 shared publicationsAdeera Levin
Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, Canada
12 shared publicationsDeenaz Zaidi
Medicine, University of Alberta, Edmonton, Alberta, Canada
12 shared publications- Marcello Tonelli
Department of Medicine, University of Calgary, Calgary, Canada
12 shared publications Aminu K. Bello
Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
11 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , 250-260.e1
Temporal Trends in the Complexity of Nephrology Inpatients: A Population-Based Cohort Study
- 22 May 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 88 (2) , 250-260.e1
Open AccessTemporal Trends in the Complexity of Nephrology Inpatients: A Population-Based Cohort Study
- Open Access
- 17 December 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001953
Initiatives to enhance referral patterns from primary care to specialist kidney care:a systematic review and meta-analysis
Objectives: To highlight data on interventions aimed at enhancing referral patterns from primary care to nephrology. Design: Systematic review and meta-analysis. Data sources: MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science and PsycINFO. Eligibility criteria: Studies reporting interventions aimed at decreasing referral volume, reducing wait times and/or increasing guideline-concordant referrals in adult patients with chronic kidney disease from primary care to specialist kidney care, from inception to 15 April 2024. Data extraction and synthesis: Studies were subcategorised based on taxonomy of initiatives, type of intervention and single versus multi-faceted interventions. Our primary outcomes were changes to referral volume, wait times and proportion of guideline-concordant referrals. Data were pooled using a random effects model and a meta-analysis was conducted using pooled mean difference (MD) and OR. Results: 20 studies used single and 13 used more than one intervention. Overall, interventions resulted in an increase in total referrals (MD: 19 referrals per month, 95% CI 7 to 30; I 2 =98%; p2 =100%; p=0.08). These effects were consistent when stratified by single versus multi-faceted interventions, and by taxonomy of interventions. Interventions categorised as financial, regulatory or legislative incentives (n=2) led to an increase in guideline-concordant referrals (OR: 1.15, 95% CI 1.02 to 1.29; I 2 : 0%; p=0.02). Organisational changes showed a non-significant reduction in wait time of 24 days (95% CI −64 to 15, I 2 =99%; p=0.23) but tended to decrease guideline concordant referrals (OR: 0.17, 95% CI 0.03 to 0.86; I 2 : 100%; p=0.03). Conclusion: Organisational changes decreased wait times. Overall, interventions increased referral volume and decreased guideline-concordant referrals. The data have implications for designing programmes to improve primary care-nephrology interface in kidney disease management.
- 17 December 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001953
Open AccessInitiatives to enhance referral patterns from primary care to specialist kidney care:a systematic review and meta-analysis
Objectives: To highlight data on interventions aimed at enhancing referral patterns from primary care to nephrology. Design: Systematic review and meta-analysis. Data sources: MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science and PsycINFO. Eligibility criteria: Studies reporting interventions aimed at decreasing referral volume, reducing wait times and/or increasing guideline-concordant referrals in adult patients with chronic kidney disease from primary care to specialist kidney care, from inception to 15 April 2024. Data extraction and synthesis: Studies were subcategorised based on taxonomy of initiatives, type of intervention and single versus multi-faceted interventions. Our primary outcomes were changes to referral volume, wait times and proportion of guideline-concordant referrals. Data were pooled using a random effects model and a meta-analysis was conducted using pooled mean difference (MD) and OR. Results: 20 studies used single and 13 used more than one intervention. Overall, interventions resulted in an increase in total referrals (MD: 19 referrals per month, 95% CI 7 to 30; I 2 =98%; p2 =100%; p=0.08). These effects were consistent when stratified by single versus multi-faceted interventions, and by taxonomy of interventions. Interventions categorised as financial, regulatory or legislative incentives (n=2) led to an increase in guideline-concordant referrals (OR: 1.15, 95% CI 1.02 to 1.29; I 2 : 0%; p=0.02). Organisational changes showed a non-significant reduction in wait time of 24 days (95% CI −64 to 15, I 2 =99%; p=0.23) but tended to decrease guideline concordant referrals (OR: 0.17, 95% CI 0.03 to 0.86; I 2 : 100%; p=0.03). Conclusion: Organisational changes decreased wait times. Overall, interventions increased referral volume and decreased guideline-concordant referrals. The data have implications for designing programmes to improve primary care-nephrology interface in kidney disease management.
- Open Access
- 27 May 2025
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 46 (4) , 400-403
Estimating the costs and amount of recyclable polyvinyl chloride plastic waste associated with discarded Icodextrin
There is limited data characterizing healthcare waste associated with peritoneal dialysis (PD). In Canada, Icodextrin for continuous cycling PD (CCPD) is only available as 2.5L bags for one-time use, and any remaining volume that is not used for a dwell is discarded. The environmental impact of this practice has not been well characterized. As such, we sought to estimate the costs associated with discarded Icodextrin and associated polyvinyl chloride (PVC) plastic waste production within our renal program. We conducted a cross-sectional audit of all patients utilizing CCPD in the Alberta Kidney Care South program in Canada in 2022. Icodextrin fill volume data were captured and the costs associated with Icodextrin use were calculated. Among patients on CCPD, the average fill volume for Icodextrin was 1273 mL, suggesting that an average of 1227 mL was discarded. In fact, 88% of patients used dwell volumes ≤1.5L. In 2021, our program spent $1.27 million CAD on Icodextrin for CCPD. Given that an average of 49% of each 2.5L bag was discarded, we estimate that the annual value of wasted Icodextrin among patients being treated with CCPD in our program was $622,300 CAD, or $3036 CAD per patient. Annual PVC waste was calculated to be 25.9 kg per patient, and we estimate that PVC waste could be reduced by 35% if there was access to 1.5L Icodextrin solutions. Our work suggests that the availability of Icodextrin bags that are better aligned with volumes used by patients could reduce healthcare costs and PVC waste.
- 27 May 2025
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 46 (4) , 400-403
Open AccessEstimating the costs and amount of recyclable polyvinyl chloride plastic waste associated with discarded Icodextrin
There is limited data characterizing healthcare waste associated with peritoneal dialysis (PD). In Canada, Icodextrin for continuous cycling PD (CCPD) is only available as 2.5L bags for one-time use, and any remaining volume that is not used for a dwell is discarded. The environmental impact of this practice has not been well characterized. As such, we sought to estimate the costs associated with discarded Icodextrin and associated polyvinyl chloride (PVC) plastic waste production within our renal program. We conducted a cross-sectional audit of all patients utilizing CCPD in the Alberta Kidney Care South program in Canada in 2022. Icodextrin fill volume data were captured and the costs associated with Icodextrin use were calculated. Among patients on CCPD, the average fill volume for Icodextrin was 1273 mL, suggesting that an average of 1227 mL was discarded. In fact, 88% of patients used dwell volumes ≤1.5L. In 2021, our program spent $1.27 million CAD on Icodextrin for CCPD. Given that an average of 49% of each 2.5L bag was discarded, we estimate that the annual value of wasted Icodextrin among patients being treated with CCPD in our program was $622,300 CAD, or $3036 CAD per patient. Annual PVC waste was calculated to be 25.9 kg per patient, and we estimate that PVC waste could be reduced by 35% if there was access to 1.5L Icodextrin solutions. Our work suggests that the availability of Icodextrin bags that are better aligned with volumes used by patients could reduce healthcare costs and PVC waste.
- 24 March 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (3) , e70027
Cytomegalovirus‐Induced Arterial Intimal Fibrosis in the Kidney Transplant
- 24 March 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (3) , e70027
Cytomegalovirus‐Induced Arterial Intimal Fibrosis in the Kidney Transplant
- Open Access
- 19 November 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (2) , 272-283
Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks
Key Points: Among 257 newly created arteriovenous fistulas, primary nonfunction occurred in 49%, and only 55% were ultimately used for dialysis. Loss of arteriovenous fistula patency was lower when competing risks were accounted for compared with conventional Kaplan–Meier analysis. We present icon-array plots that summarize our data and may be used a decision aid for patients in the future. Background: Many patients with newly created arteriovenous fistulas (AVFs) may die before the AVF is needed for hemodialysis. However, formal competing risks (CRs) frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary nonfunction and describe long-term patency using a CR framework. Methods: We conducted a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary nonfunction. Secondary outcomes included loss of primary patency, loss of assisted primary patency, and loss of secondary functional patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male, with mean age 62.3 years and median follow-up 18.5 months (range, 0.02–180 months). Of 257 participants, 50 could not be assessed for function or primary nonfunction, usually because of death. Of the remaining 207, 102 (49.3%) had primary nonfunction, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of CRs led to biased results from Kaplan–Meier analyses of lost patency. When accounting for CRs, loss of primary patency among AVFs with established function was 36.6%, 65.5%, and 66.2%, at 1, 3, and 5 years, respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for CRs and primary nonfunction. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.
- 19 November 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (2) , 272-283
Open AccessProspective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks
Key Points: Among 257 newly created arteriovenous fistulas, primary nonfunction occurred in 49%, and only 55% were ultimately used for dialysis. Loss of arteriovenous fistula patency was lower when competing risks were accounted for compared with conventional Kaplan–Meier analysis. We present icon-array plots that summarize our data and may be used a decision aid for patients in the future. Background: Many patients with newly created arteriovenous fistulas (AVFs) may die before the AVF is needed for hemodialysis. However, formal competing risks (CRs) frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary nonfunction and describe long-term patency using a CR framework. Methods: We conducted a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary nonfunction. Secondary outcomes included loss of primary patency, loss of assisted primary patency, and loss of secondary functional patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male, with mean age 62.3 years and median follow-up 18.5 months (range, 0.02–180 months). Of 257 participants, 50 could not be assessed for function or primary nonfunction, usually because of death. Of the remaining 207, 102 (49.3%) had primary nonfunction, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of CRs led to biased results from Kaplan–Meier analyses of lost patency. When accounting for CRs, loss of primary patency among AVFs with established function was 36.6%, 65.5%, and 66.2%, at 1, 3, and 5 years, respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for CRs and primary nonfunction. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.
- Open Access
Effect of metformin use on graft and patient survival in kidney transplant recipients with type 2 diabetes: a systematic review protocol
Introduction: Metformin is a first-line antihyperglycaemic agent for type 2 diabetes (T2DM). In addition to glycaemic control, it offers benefits related to cardiovascular health, weight neutrality and metabolic syndrome. However, its benefits in kidney transplant recipients remain unclear as metformin use is controversial in this population due to a lack of evidence and there are recommendations against its use in patients with poor kidney function. Hence, we seek to describe a protocol for a systematic review, which will assess the impact of metformin use on graft survival and mortality in kidney transplant recipients. Methods: This protocol was guided by the standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015. We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL and Web of Science Core Collection for relevant studies conducted in kidney transplant recipients using metformin, which report outcomes related to graft and patient survival. All studies meeting these criteria in adults and published in English from inception to 2023 will be included in our review. We will employ the Cochrane Risk of Bias Tool 2 for randomised controlled trials and the Risk of Bias in Non-randomised Studies of Intervention for non-randomised studies. We will present our data and study characteristics in a table format and determine if a meta-analysis can be performed by clinical and methodological heterogeneity, using the I 2 statistics. If a meta-analysis cannot be performed, we will provide a narrative synthesis of included studies using the Synthesis Without Meta-Analysis Reporting Guideline. Ethics and dissemination: Ethical approval will not be required for this review as the data used will be extracted from already published studies with publicly accessible data. As this study will assess the impact of metformin use on graft and patient survival in kidney transplant recipients, evidence gathered through it will be disseminated using traditional approaches that include open-access peer-reviewed publication, scientific presentations and a report. We will also disseminate our findings to appropriate academic bodies in charge of publishing guidelines related to T2DM and transplantation, as well as patient and research centred groups. PROSPERO registration number: CRD42023421799.
Open AccessEffect of metformin use on graft and patient survival in kidney transplant recipients with type 2 diabetes: a systematic review protocol
Introduction: Metformin is a first-line antihyperglycaemic agent for type 2 diabetes (T2DM). In addition to glycaemic control, it offers benefits related to cardiovascular health, weight neutrality and metabolic syndrome. However, its benefits in kidney transplant recipients remain unclear as metformin use is controversial in this population due to a lack of evidence and there are recommendations against its use in patients with poor kidney function. Hence, we seek to describe a protocol for a systematic review, which will assess the impact of metformin use on graft survival and mortality in kidney transplant recipients. Methods: This protocol was guided by the standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015. We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL and Web of Science Core Collection for relevant studies conducted in kidney transplant recipients using metformin, which report outcomes related to graft and patient survival. All studies meeting these criteria in adults and published in English from inception to 2023 will be included in our review. We will employ the Cochrane Risk of Bias Tool 2 for randomised controlled trials and the Risk of Bias in Non-randomised Studies of Intervention for non-randomised studies. We will present our data and study characteristics in a table format and determine if a meta-analysis can be performed by clinical and methodological heterogeneity, using the I 2 statistics. If a meta-analysis cannot be performed, we will provide a narrative synthesis of included studies using the Synthesis Without Meta-Analysis Reporting Guideline. Ethics and dissemination: Ethical approval will not be required for this review as the data used will be extracted from already published studies with publicly accessible data. As this study will assess the impact of metformin use on graft and patient survival in kidney transplant recipients, evidence gathered through it will be disseminated using traditional approaches that include open-access peer-reviewed publication, scientific presentations and a report. We will also disseminate our findings to appropriate academic bodies in charge of publishing guidelines related to T2DM and transplantation, as well as patient and research centred groups. PROSPERO registration number: CRD42023421799.
- Open Access
- 8 May 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-13
Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas
Background: There is a lack of contemporary data describing global variations in vascular access for hemodialysis (HD). We used the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to highlight differences in funding and availability of hemodialysis accesses used for initiating HD across world regions. Methods: Survey questions were directed at understanding the funding modules for obtaining vascular access and types of accesses used to initiate dialysis. An electronic survey was sent to national and regional key stakeholders affiliated with the ISN between June and September 2022. Countries that participated in the survey were categorized based on World Bank Income Classification (low-, lower-middle, upper-middle, and high-income) and by their regional affiliation with the ISN. Results: Data on types of vascular access were available from 160 countries. Respondents from 35 countries (22% of surveyed countries) reported that > 50% of patients started HD with an arteriovenous fistula or graft (AVF or AVG). These rates were higher in Western Europe (n = 14; 64%), North & East Asia (n = 4; 67%), and among high-income countries (n = 24; 38%). The rates of > 50% of patients starting HD with a tunneled dialysis catheter were highest in North America & Caribbean region (n = 7; 58%) and lowest in South Asia and Newly Independent States and Russia (n = 0 in both regions). Respondents from 50% (n = 9) of low-income countries reported that > 75% of patients started HD using a temporary catheter, with the highest rates in Africa (n = 30; 75%) and Latin America (n = 14; 67%). Funding for the creation of vascular access was often through public funding and free at the point of delivery in high-income countries (n = 42; 67% for AVF/AVG, n = 44; 70% for central venous catheters). In low-income countries, private and out of pocket funding was reported as being more common (n = 8; 40% for AVF/AVG, n = 5; 25% for central venous catheters). Conclusions: High income countries exhibit variation in the use of AVF/AVG and tunneled catheters. In low-income countries, there is a higher use of temporary dialysis catheters and private funding models for access creation.
- 8 May 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-13
Open AccessGlobal variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas
Background: There is a lack of contemporary data describing global variations in vascular access for hemodialysis (HD). We used the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to highlight differences in funding and availability of hemodialysis accesses used for initiating HD across world regions. Methods: Survey questions were directed at understanding the funding modules for obtaining vascular access and types of accesses used to initiate dialysis. An electronic survey was sent to national and regional key stakeholders affiliated with the ISN between June and September 2022. Countries that participated in the survey were categorized based on World Bank Income Classification (low-, lower-middle, upper-middle, and high-income) and by their regional affiliation with the ISN. Results: Data on types of vascular access were available from 160 countries. Respondents from 35 countries (22% of surveyed countries) reported that > 50% of patients started HD with an arteriovenous fistula or graft (AVF or AVG). These rates were higher in Western Europe (n = 14; 64%), North & East Asia (n = 4; 67%), and among high-income countries (n = 24; 38%). The rates of > 50% of patients starting HD with a tunneled dialysis catheter were highest in North America & Caribbean region (n = 7; 58%) and lowest in South Asia and Newly Independent States and Russia (n = 0 in both regions). Respondents from 50% (n = 9) of low-income countries reported that > 75% of patients started HD using a temporary catheter, with the highest rates in Africa (n = 30; 75%) and Latin America (n = 14; 67%). Funding for the creation of vascular access was often through public funding and free at the point of delivery in high-income countries (n = 42; 67% for AVF/AVG, n = 44; 70% for central venous catheters). In low-income countries, private and out of pocket funding was reported as being more common (n = 8; 40% for AVF/AVG, n = 5; 25% for central venous catheters). Conclusions: High income countries exhibit variation in the use of AVF/AVG and tunneled catheters. In low-income countries, there is a higher use of temporary dialysis catheters and private funding models for access creation.